We sought a method for any reader to quantify the limit, imposed by variability, to sustainably observable R 2 between any baseline predictor and response marker. We then apply this to echocardiographic measurements of mechanical dyssynchrony and response. , which is far below 1.0, and can easily be calculated by readers using formulas presented here. Community awareness of this low ceiling may help resist future claims. Reliable individualized response prediction, using methods originally designed for group-mean effects, may never be possible because it has 2 currently unavailable and perhaps impossible prerequisites: 1) excellent blinded test-retest reproducibility of dyssynchrony; and 2) response markers reproducible over time within nonintervened individuals. Dispassionate evaluation, and improvement, of test-retest reproducibility is required before any further claims of strong prediction. Prediction studies should be designed to resist bias. (J Am Coll Cardiol Img 2012;5:1046-65)
1) spontaneous variability of response markers; and 2) test-retest variability of dyssynchrony measurements.
Second, we contrasted published R 2 values between externally monitored randomized controlled trials and highly skilled single-center studies (HSSCSs). iventricular pacing is thought to deliver benefit in heart failure through resynchronization of dyssynchronous cardiac mechanical function, hence the term cardiac resynchronization therapy (1) (2) (3) (4) (5) (6) . Some studies (7) (8) (9) demonstrate strong relationships (high coefficient of determination, R 2 values) between baseline mechanical dyssynchrony and echocardiographic outcome measures, whereas others (10 -12) show much weaker relationships. Most guidelines for selecting patients for biventricular pacing emphasize electrical dyssynchrony manifested as wide QRS duration rather than mechanical dyssynchrony (13) , although pressure is growing from increasing numbers of positive studies reporting an association between baseline dyssynchrony and ventricular response. One country's guidelines already include mechanical dyssynchrony in selection (14) .
R E S U L T S Inherent variability of response markers causes a contraction factor in
Tantalizing glimpses of reliable prediction of response continue to drive the search for mechanical dyssynchrony markers or multivariate combination algorithms to provide better prediction. But is this approach wise? Why do studies disagree? Reports of R 2 exceeding 1.0 would be recognized as incorrect, but is the real upper limit of sustainably observable R 2 really 1.0, or something lower? How can one calculate the highest plausible R 2 between dyssynchrony and response? How should we interpret this clinically, and does it affect how we design future research?
The ceiling on R 2 depends upon natural variability of dyssynchrony markers and of response markers. Blinded test-retest reproducibility data on mechanical dyssynchrony markers (15, 16) and commonly used outcome markers of reverse remodeling are scarce. In this study we collate these and thereby calculate the true upper limit on plausible sustainably observable R 2 between dyssynchrony markers and echocardiographic response.
We evaluate the implications for design and interpretation of studies seeking clinically reliable markers of mechanical dyssynchrony in particular, and for studies making claims of individualized prediction of response to any intervention in general.
M E T H O D S
Quantitative separation of device-mediated, versus spontaneous, changes in left ventricular ejection fraction (LVEF). Randomized trials of biventricular pacing are the best way to separate spontaneous changes from device-induced changes in cardiac function. Patients undergoing biventricular pacing have 2 drivers of pre-to-post change in the chosen echocardiographic outcome measure (e.g., change in left ventricular ejection fraction [⌬LVEF] ). First, inherent phenomena unrelated to biventricular pacing, including true biological variability and measurement error, will contribute to individual patients' ⌬LVEF. The variance (square of standard deviation [SD 2 ]) of ⌬LVEF in the control patients in a randomized trial measures the size of this inherent scatter between successive measurements over time. Second, the device itself imposes an effect over and above the inherent variation. Because different patients (presumably) gain different amounts of effect from the device, ⌬LVEF is more widely spread in the device patients than the control patients. The extra variance in ⌬LVEF in the device patients is the variance caused by the device (Fig. 1 ). Only this extra variance, caused by the device, has any hope of being predicted by baseline dyssynchrony.
Meanwhile, baseline dyssynchrony markers also have inherent variability within a given patient over time. Only test-retest reproducibility studies reveal the extent of this. This is also true of multivariate combination algorithms used to score dyssynchrony because each component contributes something to inherent variability.
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When correlating (r) two variables, such as mechanical dyssynchrony and echocardiographic response, or determining the predictive value of one on the other (R 2 ), the measurement variability of both combine to depress the observable relationship strength (Fig. 2) (17) . We term this the R 2 contraction factor because of the following relationship (Equation 1):
where underlying R 2 is the potential correlation between the variables if all measurement noise could be eradicated. The online appendix shows full details. The R 2 contraction factor is also a ceiling on sustainably observable R 2 values because the underlying R 2 cannot exceed 1.0. The R 2 contraction factor has 2 contributors: 1) contraction from response irreproducibility; and 2) contraction from dyssynchrony irreproducibility. Both are easy to calculate if data are available. Calculating the R 2 contraction factor arising from response irreproducibility requires the SD of the ⌬ in the outcome measure in both the control arm and device arm of a randomized control trial. It is not sufficient to know the distribution of the initial and final LVEFs. Rather, the distribution of the change, that is, the SD of ⌬, is needed. This can be used in the following calculation (Equation 2):
A similar formula is used for the mechanical dyssynchrony measure. The 2 contraction factors are then multiplied to determine the combined contraction factor (Equation 3). The MIRACLE-ICD II (Multicenter InSync ICD Randomized Clinical Evaluation II) trial (18) can be used as a worked example. In the control arm, ⌬LVEF has an SD of 6.2; in the biventricular pacing arm, ⌬LVEF has an SD of 8. Therefore, the contraction factor imposed on R 2 by the response marker LVEF is 1 -(6.2/8) 2 ϭ 0.40. Thus in populations like those in MIRACLE-ICD, even with an imaginary perfectly comprehensive and perfectly reproducible dyssynchrony marker, the highest R 2 that could be sustainably observed with ⌬LVEF would be 0.40.
In reality, mechanical dyssynchrony markers or scores do not have perfect test-retest reproducibility and so impose their own contraction factor. If, for example, the dyssynchrony marker imposed a contraction factor of 0.50, then the combined contraction factor would be 0.40 ϫ 0.50 ϭ 0.20. This means that even if the marker ]) of the change in LVEF (∆LVEF) (top row, left panel). Those undergoing CRT have a further change in LVEF over and above inherent changes, widening the spread or variance in ∆LVEF (top row, right panel). Only the incremental change above inherent change is attributable to the device and only this component of variance of ∆LVEF is predictable by any baseline marker. (Although it is the variances of ∆LVEF that matter, the figure displays SDs as a visual proxy.) When the SD of the ∆LVEF (SD∆) is much larger in the biventricular pacing arm of a trial than in the control arm (middle row), there is good scope for predicting response. When the SD∆ is not much larger in the biventricular pacing arm than in the control arm (bottom row), the scope for predictability is much smaller.
is completely comprehensive in describing all aspects of dyssynchrony (and there are no confounding features, e.g., scar or lead position), the maximum R 2 observable is still only 0.20.
Data extraction from published studies. A systematic review of studies assessing the response to biventricular pacing was performed using the EMBASE and MEDLINE databases (Fig. 3) . The terms cardiac resynchronization therapy, biventricular pacing, and dyssynchrony were used and abstracts reviewed for relevance. All published studies that assessed mechanical dyssynchrony markers against ⌬LVEF, ⌬LV endsystolic volume (ESV), and ⌬LV end-diastolic volume (EDV) were analyzed and had R 2 data extracted (7-9) (Online Appendix References 1-40). R 2 was calculated where necessary by squaring the correlation coefficient between the mechanical dyssynchrony marker and outcome measure, using the published data in tabular, text, or graphic form. Weighted averages of the R 2 were calculated using the size of the study.
Studies reporting mechanical dyssynchrony markers were assessed to determine the test-retest variability of the markers and whether data were collected after formal enrollment with blinding.
Studies that report SD within 1 patient and the SD across the population can have the R 2 contraction factor from the mechanical dyssynchrony marker calculated as 1 -(SD within-patient /SD between-patient ) 2 . Where test-retest variability is given as a correlation coefficient r, it was used as an estimate of the R 2 contraction factor imposed by the dyssynchrony marker.
The landmark externally monitored randomized controlled trials (EM-RCTs) of biventricular pacing were assessed to determine the SD of ⌬LVEF, ⌬LVESV, and ⌬LVEDV in the control and intervention arms (Online Appendix References [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] Imagine a universally comprehensive dyssynchrony marker that can perfectly predict response, as long as measurement noise could somehow be eliminated (A). In practice there is natural variability in measurements of ejection fraction (B) and of the dyssynchrony marker (C). These noise properties combine together multiplicatively to depress the actually observable R 2 value (D). In this example case, it is mathematically impossible for an R 2 value over 0.56 to be observed sustainably.
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R E S U L T S
Reported R 2 for echocardiographic response in EM-RCTs and highly skilled single-center studies.
Fifty-eight reports were identified and assessed. The majority were retrospective cohort studies with or without a control group, performed in highly skilled single centers (HSSC) with specific interest in echocardiographic dyssynchrony markers and a track record of innovation in the field (Online Appendix references 41-58). The reported R 2 in these studies between individual dyssynchrony markers and echocardiographic response to biventricular pacing (⌬LVEF, ⌬LVESV, or ⌬LVEDV) are tabulated in Table 1 .
R 2 values were weighted according to etiology of heart failure (ischemic heart disease vs. idiopathic); no statistically significant difference was found between the 2 groups (p ϭ 0.38).
EM-RCTs establishing the use of biventricular pacing were assessed. Primary and secondary publications report a wide variety of potential R 2 between the outcome of biventricular pacing and baseline measures of dyssynchrony ( (Fig. 4) .
R
2 contraction factor arising from outcome variable.
EM-RCTs provided data sufficient to estimate the R 2 contraction factor for the commonly used echocardiographic outcome measures ( Table 2 ) and clinical response markers (Table 3 ). All 3 echocardiographic outcome variables (⌬LVEF, ⌬LVESV, and ⌬LVEDV) have sufficient variability in the control populations to give R 2 contraction factors that limit observed R 2 to modest values, even if the predictive dyssynchrony marker or combination algorithm was perfect and had no variability. We assessed the published variability of mechanical dyssynchrony markers between repeated echocardiograms in the same patient (test-retest reproducibility) (Table 4) . Only 3 studies report the true test-retest variability needed to calculate the contraction factor for each dyssynchrony marker. In one, within-patient variation and between-patient variation was small (15) . The second assessed testretest reproducibility of tissue Doppler imaging mechanical dyssynchrony markers and presented the R 2 contraction factor directly when measured by 2 separate readers, giving an average value of 0.35 (16) . The third randomized patients to biventricular pacing or medical therapy and reported the change in dyssynchrony indexes remeasured in the control population (70). The mean change and its SD were provided to us by the authors. Overall, the available contraction factors range from 0.16 to 0.92, averaging ϳ0.6.
Combined R 2 contraction factor. The combined R 2 contraction factor between echocardiographic response and a dyssynchrony marker is calculated by multiplication. We estimate that for ⌬LVEF it is 0.29 (0.6 ϫ 0.48); for ⌬LVEDV, 0.24 (0.6 ϫ 0.40); and for ⌬LVESV, 0.30 (0.6 ϫ 0.50). These are point estimates and may overestimate or underestimate the true combined contraction factor. Table 5 displays the likely values with the most likely region in boldface.
Comparing study design between HSSCSs and EM-RCTs.
We assessed whether studies specified 3 key design features that limit bias: 1) predictive marker stated to be measured blinded to outcome; 2) outcome marker stated to be measured blinded to the patient's treatment with biventricular pacing; and 3) patients stated to be formally enrolled before the 
Figure 3. Systematic Search Strategy
A systematic review of the literature was undertaken to identify studies using baseline echocardiographic mechanical dyssynchrony markers to predict change in echocardiographic response markers (∆LVEF, ∆LVESV, and ∆LVEDV). Abbreviations as in Figure 1 .
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measurements were made ( Table 6 ). To determine the impact of publication bias a funnel plot was performed (Fig. 5) . Study size had a weak but positive relationship with the publishing larger R 2 values (r 2 for this relationship ϭ 0.25, p Ͻ 0.01) indicating the evidence of publication bias favoring positive studies.
To determine the impact of study design that affected R 2 , we plotted R 2 against study size and the number of bias-resistance features (Fig. 6 ). Each study scored 0 or 1 point for each of 3 features. When the presence of a feature was unclear, no point was given. While smaller studies showed a tendency to report higher R 2 values than larger studies, the number of bias-resistance features showed a stronger influence. Studies designed from the outset to resist bias never showed high R 2 values. Very high R 2 values occurred exclusively in studies that described little or nothing done to resist bias.
D I S C U S S I O N
This article shows how to determine the ceiling on the sustainable R 2 values between any baseline marker and subsequent response to any intervention, such as biventricular pacing. Readers can use this ceiling, or contraction factor, to judge whether an R 2 is credible. The greater the test-retest variability in any predictor and/or response-whether due to biological factors, measurement error, or 
random noise-the lower the limit on the sustainably observable R 2 (20, 22) . This approach could be used to screen the plausibility of any claim of a baseline marker apparently predicting the effect of any intervention on any variable.
The ceiling to observed R 2 . Spontaneous variability in both dyssynchrony markers and response markers conspire to limit observed R 2 to only low values. This happens with any etiology of heart failure, and for both single-variable and multivariate risk indexes. HSSCSs consistently report higher R 2 values than EM-RCTs, and frequently exceed the mathematical ceiling. This suggests that the HSSCS method is in error.
This study exposes the prerequisites for reliable prediction of individual response, which are challenging. Even a theoretical, perfectly comprehensive dyssynchrony marker (whether a single-variable or multivariate algorithm) that incorporates every facet of responsiveness to biventricular pacing will still have a low ceiling. This is because it will have spontaneous variability, as will the marker of response, and these 2 contraction factors multiply to limit R 2 . These findings are important because some studies forget the impact of variability within predictors and response markers, and so have unrealistic expectations. Our study shows that many published Variance weighted average 0.48 *The maximal possible R 2 for any parameter to the ∆EF in each study is presented for each study. †The ∆LVESV, ∆LVEDV, and ∆LVEF values in RETHINQ have distinctive properties making them unsuitable for this analysis. First, the test-retest reproducibility (∆ in controls) had a variance a magnitude smaller than the other studies. Second, the distributions of ∆ for these echo markers were skewed with a curtailment of the tail trending toward deterioration, and extension of the tail trending toward improvement. This skew was not present in continuous outcome markers in which only a single measurement was possible, such as exercise duration (Online Appendix reference 55). The RETHINQ protocol blinded assessors to allocation but did not report blinding echocardiographers prior to measurements. It also permitted exclusion of extreme values, as per clinical convention. The published data suggest this latitude was exercised asymmetrically, favoring an appearance of improvement, which is common in clinical practice because the psychological impact of a deterioration in individual patients is important. However, from a pure research viewpoint, this skew of ∆s makes the data unsuitable for evaluating the scientifically desired blinded test-retest reproducibility of variables (41) (42) (43) . Boldface represents the calculated R 2 from each study. MIRACLE-ICD II ϭ Multicenter InSync ICD Randomized Clinical Evaluation II; RESPOND ϭ Resynchronization in Patients with Heart Failure and a Normal QRS Duration; RETHINQ ϭ Resynchronization Therapy in Normal QRS study; SD ϭ standard deviation; other abbreviations as in Table 1 .
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studies markedly overestimate the predictive effect of dyssynchrony markers compared with studies having formal enrollment and blinded analysis.
This should not be mistaken as a criticism of workers' integrity, but rather a failing in all of us in underestimating the importance of aspects of study design that might appear superficially uninteresting or trivial. The time-honored approach of hypothesizing correlations and then finding confirmatory evidence in one's local clinical data is incorrect because it provides results that are not only too high but actually above the mathematical ceiling. Strong prediction is sustainable only if both contraction factors are almost 1. Not only are they nowhere near 1, but comparatively little effort has been put into establishing what they are. Can the contraction factor be improved? Only genuinely reducing variability in both predictors and response markers can improve the contraction factor. Formal blinded test-retest reproducibility ("other day, other hands, other eyes") of the markers must be carried out. Methods should then be refined or rejected, and the cycle iterated, until a protocol is obtained that reliably delivers high reproducibility in independent, blinded hands. It is the measurement protocol, and not the operators, that is being tested. If wide test-retest variability is observed, then that is the result of the study design and it should be reported dispassionately. Operators should not be blamed for reporting the truth. Some planners mistake published data on remeasurement for test-retest reproducibility. Others collect it too late to change the study protocol. Worse still, some collect it only under pressure from journal reviewers after study completion, at which stage there is overwhelming pressure to report a narrow variability even if unrepresentative.
Only markers with strong test-retest reproducibility should even be considered for expensive trials of individualized prediction (Table 5 ). Unless very much narrower than the population distribution of these variables, the markers should be rejected or refined before initiating any major study. Effort expended on maximizing the ratio of signal (between-patient genuine variability) to noise (within-patient variability) is indispensable to improving prediction of response. Opportunities and limits of replicate averaging. Increasing patient recruitment will not raise the ceiling on sustainably observable R 2 ; instead it enforces the same mathematical ceiling more firmly by reducing scope for fluke associations.
The impact of noise can, however, be reduced by making multiple replicate measures per patient and using the average (19,21) . However, signal itself is *The maximal achievable R 2 column estimates the maximum R 2 that any predictor could find when correlated against any of these non-echocardiographic outcome measures. Boldface represents the calculated R 2 from each study. 6MWD ϭ 6-minute walk distance; COMPANION ϭ Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure Trial; SDD ϭ standard deviation of difference (∆); VO 2 ϭ oxygen consumption; V E /V CO2 ϭ ratio of minute ventilation (V E ) and minute production of CO 2 (V CO2 ), a measure of ventilatory response to exercise; other abbreviations as in Table 1 . 
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not increased by replication and so sustainably observable R 2 can rise as high as the underlying R 2 but no higher. When performing replicates for averaging, researchers must avoid the natural temptation to choose replicates that appear similar, ignoring apparent outliers. Measurements are best made without reference to each other, to maximize the statistical advantages of replicate averaging (22, 23) .
Researchers should also resist the clinically natural temptation to choose the replicate most representative of the patients' full clinical status, because doing so may innocently but powerfully bias the result toward confirming whatever association the researcher believes (24) . Clinical practice is heavily dependent on such application of common sense, but unfortunately this is why routinely acquired unblinded clinical measurements are unsuitable for testing whether clinically believed associations are true. The stronger the belief, and the wider the range of values available (22, 24) , the greater the danger of self-deception.
In practice, replicates are often made a few seconds apart, but this does not capture variability over hours and days, or sensitivity to imperceptible differences in probe position (23) . Paradoxically, an average of replicates would be more consistent over time if the measurements aggregated within Where test-retest reproducibility is available, the R 2 contraction factor applied by variability in the dyssynchrony marker can be found. †In the Palmieri study, the data for SD within 1 patient are from their Table 3 , and the SD across the population is from their Table 1 . Boldface represents the calculated R 2 from each study. Please see the Online Appendix for reference citations. each average were done on separate days (i.e., their internal variability had been maximized) rather than on successive beats (23) . Averaging can only reduce the influence of variability the full spread of which is captured among the data points averaged. The final advantage of replicate measurement, if "conducted on another day, acquired by other hands, viewed by other eyes," is that it exposes irreproducible markers for early dismissal.
Why some HSSCSs report higher R 2 (and higher than mathematically sustainable limits) than do EM-RCTs. Several factors may have contributed to HSSCSs' reporting significantly higher R 2 values than the sustainable values found in EM-RCTs (Fig. 4) . CHANCE ASSOCIATION. High R 2 values may have been found by statistical chance and then published with preferential enthusiasm. This could occur as submission bias from research groups and/or acceptance bias from journals.
'RUSSIAN-DOLL' PUBLICATION. Successive HSSCS publications from the same site may have overlapping patient cohorts. Patients might understandably be added to a growing database from which publications naturally arise. High R 2 occurring by chance in early cohorts would repeatedly contribute to subsequent publications.
PREFERENTIAL RECRUITMENT OF PATIENTS. Selection of extra patients who have unusually severe or mild mechanical dyssynchrony, or who have unusually large changes in the response variable, will artificially magnify R 2 .
LACK OF BLINDING. The R 2 between mechanical dyssynchrony markers and response markers can reliably inform prospective clinical practice only if each measurement is performed by observers blinded to the other relevant measurements in that patient. Mechanical dyssynchrony should be measured without knowledge of the LVEF, and vice versa. Dyssynchrony markers are sensitive to adjustment of cursor position, and operators might inadvertently "dial in" (25) the expected dyssynchrony if unblinded. Ventricular function assessment is similarly sensitive to choices during acquisition and during analysis. Clinicians are generally right to preferentially select plausible rather than implausible values. Unfortunately, applying this habit in research is dangerous, because if the clinician already believes the hypothesis, even minor and innocent influence will raise R 2 dramatically (24). Concealment of electrocardiography (which shows biventricular pacing spikes) is essential during analysis if unbiased ⌬LVEF is sought. The majority of the EM-RCTs report blinding of dyssynchrony and response measurements (Table 6) ; almost all of the HSSCSs did not.
SELECTIVE INCLUSION OR EXCLUSION OF PARTICULAR
PATIENTS. HSSCSs may receive unusual referral patterns distorting the distribution of dyssynchrony markers away from the pattern typically seen by future clinical practice and in EM-RCTs. Finally, HSSCSs, if done without the advantage of formal, sequentially numbered, prospective enrollment of patients, may end up unintentionally analyzing an incomplete subset of the population at that center (24); patients with notably strong concordance between physiological expectation and clinical response are especially unlikely to be forgotten, and their preferential recollection would persistently bias R 2 upward.
Why do inflated reports gain circulation, and how can recurrences be prevented? It is tempting to blame publication bias (i.e., failure to publish negative studies). However, the standard funnel plot (Fig. 5) shows that publication bias is a minority contributor. The overwhelming determinant is the vulnerability of the study design to bias, as shown on the combined design-and-size plot (Fig. 6 ). Nijjer et al.
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The responsibility may lie more properly with us as an audience for several weaknesses in application of normal scientific critique.
SOUND-BITE SUSCEPTIBILITY. Our community accepted uncritically the term cardiac resynchronization therapy. With repetition it became obvious that quantifying mechanical dyssynchrony (which can only refer to ventricular timings because atrium and ventricle should not be synchronous) must quantify degree of benefit. Obvious, but not necessarily true. With experimental investigation of the therapy's mechanism of action still at an early stage, we might reduce cognitive distortion by using a neutral term such as biventricular pacing (26) .
AUTHORITY AWE. Physical science audiences judge a scientific finding by the precise nature of the experiment, the attention to detail, and the track record of previous claims being verified by others. Cardiologic audiences may not apply the same level of scrutiny (in particular, bias resistance is rarely debated) and may apply the availability heuristic (judging the credibility of sources from public visibility rather than track record of reliability). Audiences could usefully restore habits from their earlier scientific training.
ANNUAL AMNESIA. Hearing each year of novel predictive markers with progressively more excellent predictive capacities, cardiologic audiences forget to ask what happened to markers of years past. If 2 different markers predict excellently, they must agree almost perfectly; if the latter is not the case, the former is not credible. Enhanced audience memory would help resist successive overstatements.
PRACTICAL PARALYSIS. In physical science, any reported efficacious new approach is rapidly tested in small experiments by the audience. Cardiologic audiences may feel unable to do this. Yet simple experiments taking only minutes can quickly reject some claims. One example is the evaluation of blinded test-retest reproducibility and the application of the formulas in this paper. Another is adjustment of interventricular delay across a wide range in a single biventricular pacemaker patient, with blinded measurement of mechanical dyssynchrony; if this does not show a clear minimum in this highly controlled environment, it cannot work across a population (27, 28) .
WISHFUL THINKING. We all want our specialty of echocardiography to be relevant. Reports of successful application are therefore intrinsically popular. But this is failure to separate our individual skill as echocardiographers from the ability of an echocardiographic technique to deliver what is claimed. Distinguishing falsity of a hypothesis from personal inadequacy requires courage but is the hallmark of science.
CRYPTIC COMMENTARY. Even when experts carefully review available methods and tabulate that dyssynchrony markers are intensely vulnerable to noise and sometimes choice of measurement location so that there is risk for "dialing in" any desired level of dyssynchrony (25) , they may be too polite to explain the quantitative implication for claims of response prediction (29) .
BIAS BLINDNESS. We frequently confuse bias (which arises from study design) with chance (which is addressed by p values). Larger study sizes cause even minor systematic biases to become more Abbreviations as in Figure 1 .
Nijjer et al. Overestimation of Cardiac Resynchronization Therapy Response Prediction statistically significant. This confusion afflicts even expert audiences, such as those writing guidelines, who often consider observational studies (if large) to be the same level of evidence ("B") as a randomized controlled trial. Yet ironically, larger observational study size increases susceptibility to bias, making them less reliable guides to therapeutic decisions.
TEST-RETEST TABOO. We frequently confuse remeasurement of identical digital images with genuine test-retest reproducibility, entirely ignoring the majority of variability, which occurs between beats. Test-retest variability can be readily checked by clinicians (30) .
RETRACTION RELUCTANCE. In science, a finding beyond the bounds of plausibility, such as fasterthan-light travel (31) , is highlighted as suspicious by the authors even with a p value ϳ2 ϫ 10 -9 . The error was found to be unrecognized measurement bias, and the scientific record corrected (32) . Our field could encourage timely retraction of clinical reports that are discovered to be unrepresentative, giving credit to authors who report what went wrong in their own studies.
Clinical implications for mechanical dyssynchrony.
This paper provides a simple method for clinicians to calculate the ceiling on plausible claims of predictability of ventricular response. It may seem surprising that variability in repeated measures can matter so much because such variability does not seem to impede normal clinical practice or trials addressing group mean effects. However, even small variability inevitably prevents accurate individualized prediction of response.
This approach may seem somewhat mathematical. However, publications stating an R 2 or correlation are making a mathematical assertion of association strength. This paper shows how the same mathematics that underlie R 2 calculations also demarcate the upper limit of plausibility, which is far below 1.0, exposing some assertions as anomalous.
Some may suspect that if ischemic scar or imperfect left ventricular lead positioning could be excluded, mechanical dyssynchrony markers might provide good prediction. These factors make prediction more difficult, that is, the ceiling is even lower than we describe here. Our calculations show that even if scarring, mispositioning, and all other confounders could be eliminated, the highest sustainable R 2 value would still be low. Nor can multivariable prediction by composite markers evade these difficulties. Spontaneous variability in response markers remains and may be worse for composites of poorly reproducible components. Thus composite markers will likely have an even lower ceiling on R 2 . The search for predictive markers stems from a desire to optimize the resource cost of biventricular pacing. However, resources expended in identifying predictors unreliably would be better expended first screening predictors and response markers for blinded test-retest reproducibility. Early exposure of poor reproducibility would forestall reports of prediction that are destined not to stand the test of time.
Implications for research into mechanical dyssynchrony.
Our analysis rejects not the concept of mechanical dyssynchrony, but rather the value of unblinded, informally enrolled studies of prediction (Fig. 5) . Outcomes are known to be better in those device recipients who have greater dyssynchrony but observational study design cannot distinguish whether the better outcome would have happened without the device, or occurred as a result of the device. The continuous-variable analysis of the CARE-HF (Cardiac Resynchronization in Heart Failure) randomized controlled trial shows both mechanisms occurring simultaneously (33) . Nondevice patients had progressively better outcomes the more dyssynchrony they had at baseline (33) .
Approaches that have worked for addressing group mean effects cannot be uncritically expected to determine which individual patients benefit the most from biventricular pacing. This would need measurements of the effect of biventricular pacing on individual patients that have narrow withinindividual error bars. Symptoms or outcomes assessed in the conventional way are not suitable, but quantitative physiological measurements could be developed to deliver this (33) (34) (35) . Wider implications for cardiologic research. Study design can overwhelmingly determine study results. In this example, a "perfect storm" of excellent plausibility-a clear survival benefit from the devices, clinical enthusiasm, unnoticed poor test-retest variability, underestimated impact of unblinded measurement, and lack of community awareness of ceilings on predictability-has made the literature as a whole unreliable.
But similar overstatements may be occurring elsewhere, unnoticed. Our cardiologic community should improve its ability to challenge claims. We must recognize that study size alone does not guarantee reliability (36) ; bias must be actively removed by careful planning. We should be emboldened to question early pioneering work because
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history shows it is often discredited later (37) (38) (39) . Negative studies may seem superficially unexciting to journals, but carefully designed studies replicable by readers, contradicting prevailing beliefs, are the lifeblood of genuine science. We should prize not extreme claims but reliable experiments that can be checked by readers. When results are incompatible, groups should collaborate to understand why.
Few real-life outcomes are overwhelmingly determined by 1 variable; almost always, multiple features (including those that cannot currently be quantified) matter and interact in a way that cannot be captured in a single diagnostic marker. Therefore, we should react with surprise if a single variable is reported to predict any outcome with high certainty.
Finally, this recent "bubble market" in mechanical dyssynchrony should inoculate our community with skepticism for claims of association strength and encourage the examination of the track record of whether previous claims have stood the test of time. Study limitations. This study is limited by the haste with which reports of prediction of biventricular pacing response arrive in the literature before independent blinded evaluations of their test-retest reproducibility of their methods. No study seems to have performed a series of blinded measurements of dyssynchrony to permit true reproducibility SD to be evaluated. We have had to use the SD of difference between just two, which is an imperfect estimate of this.
Furthermore, few reports of claimed prediction of response present sufficient information to determine the distribution of the change induced by biventricular pacing, or test-retest reproducibility of either predictors or outcome measures. We have used rigorously performed EM-RCTs, which have control populations to assess the inherent variability of response markers over time periods over which response to device implantation is normally measured. However, these control populations are only similar (through randomization) to their corresponding intervention populations, rather than being identical. Therefore, the estimates of the R 2 contraction factor may slightly under-or overestimate the true R 2 contraction factor. Individual studies may give an estimate Ͻ0, especially if the true contraction factor is near zero and/or the statistical characteristics of the ⌬ are non-normally distributed, as might occur when an analysis is unblinded.
These studies had different types of patients with differing etiologies, echocardiographic criteria, and outcome measures. This would limit the strength of a conventional meta-analysis, but it increases the generalizability of the findings from our study. No marker was strongly predictive when tested in bias-resistant designs, despite covering many spectra of patient populations. There was no relationship of the R 2 values to the proportion of patients who had ischemic etiology of heart failure.
Many different mechanical dyssynchrony markers have been assessed, some basic and some sophisticated. They are not all directly comparable. For openness and completeness, we fully report all of the markers for which R 2 ceiling was calculable (Table 1) . Most have only modest values, including the newer, more sophisticated ones. Markers involving multiple steps to measure have more sources of variation and are likely to have a worse R 2 contraction factor.
Some studies recently report not R 2 but area under curve or a sensitivity analysis. The underlying variability remains, and an equivalent of the R 2 contraction factor affects all measures of association.
New studies have chosen to measure alternative methods of echocardiographic response, such as global strain. We specifically chose to review the commonly used echocardiographic response markers (LVEF, LVESV, and LVEDV). This is because, first, these markers are commonly measured by echocardiographic laboratories. Second, they are the most familiar to clinicians. Third, it has been accepted that improvement in these is related to outcome (40) . Finally, they have been tested in formally enrolled EM-RCT settings allowing reliable assessment of spontaneous variability. Our findings, however, are applicable to all future predictors and response markers. Each must have low test-retest variability for the contraction factor to be sufficient for any chance of clinically impressive prediction of response.
C O N C L U S I O N S
No scientifically conducted study will give reliable individual patient prediction (e.g., R 2 Ͼ 0.5), by any current baseline marker of mechanical dyssynchrony, of any current marker of response to biventricular pacing, across a representative range of patients, with current measurement protocols. Unsustainably high R 2 values arise through honest efforts in HSSCSs not because the studies are small It may be time to critically reassess the utility of HSSCS literature on the prediction of ventricular response to mechanical dyssynchrony. The overstatement of relationship strength by 5-to 20-fold, and the large proportion of results exceeding the mathematically possible ceiling, indicate that unblinded studies without formal enrollment have failed us entirely.
It is not credible to attempt to usefully predict ventricular response in individual patients, or to embark on further research into such predictive power, unless 2 substantial methodologic advances arrive: 1) protocols for measuring mechanical dyssynchrony that reliably give high test-retest reproducibility in the hands of multiple centers beyond their originators, under formal blinded conditions; and 2) methods for quantifying "response" in a way that, in patients who undergo no intervention, shows minimal within-individual change over time, in blinded externally monitored analysis, over time periods similar to those over which biventricular pacing response is typically measured.
The latter may be biologically impossible, in which case reliable individualized prediction of response is impossible.
To prevent future bubble markets of ineffective diagnostics, we should not take seriously any more unblinded, unenrolled studies that make mathematically implausible claims. 
